Fig. 1

Patient disposition. *Three initial monthly injections (− 1/+ 2 weeks). The per-protocol population was defined as patients without protocol deviation and with BCVA/CRT assessments prior to any treatment (ranibizumab) at baseline and at Month 12 (n = 125). The FAS included patients who received ≥1 IVT-AFL treatment and had BCVA and CRT assessments in the study eye at baseline and during follow-up (n = 185). BCVA = best-corrected visual acuity; CRT = central retinal thickness; FAS = full analysis set; IVT-AFL = intravitreal aflibercept; SAS = safety analysis set